Publications

Full list: Google Scholar  Pubmed  

Selected recent studies

 

 

 

 

  • Vitic Z, Safory H, Jovanovic VM, Sarusi Y, Stavsky A, Kahn J, Kuzmina A, Toker L, Gitler D, Taube R, Friedel RH, Engelender S, Brodski C. BMP5/7 protect dopaminergic neurons in an α-synuclein mouse model of Parkinson’s disease. Brain. 2021 Mar 3;144(2):e15.

 

 

  • Shani,V, Safory H, Szargel R, Wang N, Cohen T, Elghani FA, Hamza H, Savyon M, Radzishevsky I, Shaulov L1 Rott R, Lim KL, Ross CA, Bandopadhyay R, Zhang H, Engelender S. Physiological and pathological roles of LRRK2 in the nuclear envelope integrity. Hum Mol Genet. 28(23):3982-3996, 2019.

 

  • Hallett PJ, Engelender S, Isacson O.Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease. J Neuroinflammation. 16(1):153, 2019.

 

  • Rott, R., Szargel, R., Shani, V., Hamza, H., Savyon, M., Bandopadhyay, R. and Engelender, S. SUMOylation and ubiquitination reciprocally regulate -synuclein degradation and pathological aggregation. Proc. Natl. Acad. Sci. U.S.A., 14:13176-13181, 2017.

 

  • Neame, S., Safory, H., Radzishevsky, I., Touitou, A., Marchesani, F., Marchetti, M., Kellner, S., Berlin, S., Foltyn, V.N., Engelender, S., Billard, J.M., Wolosker H.  The NMDA receptor activation by D-serine and glycine is controlled by an astrocytic Phgdh-dependent serine shuttle. Proc. Natl. Acad. Sci. U S A 116 (41) 20736-20742, 2019.

 

  • Engelender, S.* and Isacson, O.* The Threshold Theory for Parkinson’s disease. Trends Neurosci. 40: 4-14, 2017.* Corresponding authors

 

  • Vicente Miranda, H., Szego, É.M., Oliveira, L.M., Breda, C., Darendelioglu, E., de Oliveira, R.M., Ferreira, D.G., Gomes, M.A., Rott, R., Oliveira, M., Munari, F., Enguita, F.J., Simões, T., Rodrigues, E.F., Heinrich, M., Martins, I.C., Zamolo, I., Riess, O., Cordeiro, C., Ponces-Freire, A., Lashuel, H.A., Santos, N.C., Lopes, L.V., Xiang, W., Jovin, T.M., Penque, D., Engelender, S., Zweckstetter, M., Klucken, J., Giorgini, F., Quintas, A. and Outeiro, T.F. Glycation potentiates -synuclein-associated neurodegeneration in synucleinopathies. Brain, 140:1399-1419., 2017.

 

  • Basil, A.H., Sim, J.P.L., Lim, G.G.Y., Lin, S., Chan, H.Y., Engelender, S. and Lim, K.L. AF-6 protects against dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson’s disease. Front. Cell. Neurosci. 11:241, 2017.

 

  • Szargel, R., Shani, V., Abd Elghani, F., Mekies, L.N., Liani, E., Rott, R. and Engelender, S. The PINK1, synphilin-1, and SIAH-1 complex constitutes a novel mitophagy pathway. Hum. Mol. Genet. 25: 3476-3490, 2016.

 

  • Nucifora, F., Nucifora, L., Ng, C.-H., Arbez, N., Guo, Y., Roby, E., Shani, V., Engelender, S., Wei, D., Wang, X.-F., Li, T., Moore, D., Pletnikova, O., Troncoso, J.C., Sawa, A., Dawson, T., Smith, W., Lim, K.L., and Ross, C.A. Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1. Nature Commun. 7: 11792, 2016.

 

  • Liu, J., Li, T., Thomas, J.M., Jiang, H., Engelender, S., Ross, C.A. and Smith W.W. Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson’s disease models. Hum. Mol. Genet. 25: 672-680, 2016.

 

  • Norris, K.L., Hao R., Chen L.F., Lai C.H., Kapur M., Shaughnessy P.J., Chou D., Yan J., Taylor J.P., Engelender S., West A.E., Lim K.L., Yao T.P. Convergence of parkin, PINK1 and α-synuclein on stress-induced mitochondrial morphological remodeling. J. Biol. Chem. 290:13862-13874, 2015.

 

  • Safory, H., Neame, S., Shulman, Y., Zubedat, S., Radzishevsky, I., Rosenberg, D., Sason, H., Engelender, S., Avital, A., Hulsmann, S., Schiller, J. and Wolosker, H. The alanine-serine-cysteine-1 (Asc-1) transporter is a regulator of glycine metabolism and glycinergic inhibitory transmission: Potential relevance to hyperekplexia. EMBO Rep. 16:590-598, 2015.

 

  • Rott, R., Szargel, R., Shani, V., Bisharat, S. and Engelender S. α-Synuclein Ubiquitination and Novel Therapeutic Targets for Parkinson’s Disease. CNS Neurol Disord Drug Targets. 13: 630-637, 2014

 

  • Haskin, J., Szargel, R., Shani, V., Mekies, L.N., Rott, R., Lim, G.G., Lim, K.L., Bandopadhyay, R., Wolosker, H. and Engelender S. AF-6 is a positive modulator of the PINK1/parkin pathway and is deficient in Parkinson’s disease. Hum. Mol. Genet. 22: 2083-96, 2013.

 

  • Abeywardana, T., Lin, Y.H., Rott, R., Engelender, S.* and Pratt MR.* Site-Specific Differences in Proteasome-Dependent Degradation of Monoubiquitinated α-Synuclein. Chem Biol. 20: 1207-1213, 2013.*Corresponding authors

 

  • Engelender, S. a-Synuclein fate: Proteasome or autophagy? Autophagy 8: 418-20, 2012

 

  • Rott, R., Szargel, R., Haskin, Y., Bandopadhyay, R., Lees, A. J., Shani V. and Engelender, S. -Synuclein fate is determined by USP9X-regulated monoubiquitination. Proc. Natl. Acad. Sci. U.S.A. 108: 18666-71, 2011.